

Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients

NCT07191171

Status RECRUITING
Sponsor University Hospital, Strasbourg, France
Enrollment 800 participants

Plain Language Summary

This study is examining whether certain common medications (like antibiotics and antacids) that disrupt the gut microbiome affect how well immunotherapy works in patients with advanced non-small cell lung cancer (NSCLC).

****You may be eligible if...****

- You are 18 or older
- You have been diagnosed with non-small cell lung cancer
- You have stage IV or stage IIIC disease
- You are receiving immunotherapy as part of your cancer treatment

****You may NOT be eligible if...****

- You refuse to allow your health data to be used for research
- You are a minor (under 18)
- Your cancer is at an earlier stage (below stage IIIC)
- You are in a double-blind clinical trial where your treatment assignment is not known
- Key clinical or treatment data is not available

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (4)

- Adult (≥18 years)
- Confirmed diagnosis of NSCLC
- Stage IV or stage III-C NSCLC
- Immunotherapy treatment

Exclusion (5)

- Refusal to reuse data for scientific research purposes
- Minor patient
- Disease stage below stage III-C
- Patient included in a clinical trial with an unknown randomization arm (double-blind study)
- Lack of relevant data on concomitant treatments, biology, or clinical outcomes

Locations (1 total)

Service de Pneumologie - CHU de Strasbourg - France, Strasbourg, France

<https://clinicaltrials.gov/study/NCT07191171>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.